- Home
- WGRX vs OBIO Comparison
WGRX vs OBIO Comparison
Compare WGRX & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WGRX
- OBIO
- Stock Information
- Founded
- WGRX 2022
- OBIO 2017
- Country
- WGRX United States
- OBIO United States
- Employees
- WGRX N/A
- OBIO N/A
- Industry
- WGRX Other Pharmaceuticals
- OBIO Medicinal Chemicals and Botanical Products
- Sector
- WGRX Health Care
- OBIO Health Care
- Exchange
- WGRX Nasdaq
- OBIO Nasdaq
- Market Cap
- WGRX 140.2M
- OBIO 151.3M
- IPO Year
- WGRX 2025
- OBIO N/A
- Fundamental
- Price
- WGRX $4.32
- OBIO $4.28
- Analyst Decision
- WGRX
- OBIO Strong Buy
- Analyst Count
- WGRX 0
- OBIO 5
- Target Price
- WGRX N/A
- OBIO $15.40
- AVG Volume (30 Days)
- WGRX 184.2K
- OBIO 51.3K
- Earning Date
- WGRX 01-01-0001
- OBIO 05-12-2025
- Dividend Yield
- WGRX N/A
- OBIO N/A
- EPS Growth
- WGRX N/A
- OBIO N/A
- EPS
- WGRX N/A
- OBIO N/A
- Revenue
- WGRX $18,128,831.00
- OBIO $2,647,000.00
- Revenue This Year
- WGRX N/A
- OBIO $22.61
- Revenue Next Year
- WGRX N/A
- OBIO $16.64
- P/E Ratio
- WGRX N/A
- OBIO N/A
- Revenue Growth
- WGRX N/A
- OBIO N/A
- 52 Week Low
- WGRX $2.32
- OBIO $3.75
- 52 Week High
- WGRX $5.69
- OBIO $8.87
- Technical
- Relative Strength Index (RSI)
- WGRX N/A
- OBIO 45.19
- Support Level
- WGRX N/A
- OBIO $4.14
- Resistance Level
- WGRX N/A
- OBIO $4.67
- Average True Range (ATR)
- WGRX 0.00
- OBIO 0.34
- MACD
- WGRX 0.00
- OBIO 0.06
- Stochastic Oscillator
- WGRX 0.00
- OBIO 51.70
About WGRX Wellgistics Health Inc. Common Stock
Wellgistics Health Inc is a healthcare technology and pharmaceutical logistics company. It simplifies the logistics of prescription fulfillment from the manufacturer and provider to the patient. Its solutions provide a seamless prescription ecosystem through an integrated technology platform, wholesale distribution, and fulfillment network focused on Independent Pharmacies and Specialty Lite medications.
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the global commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.